These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 13244856

  • 21. The FDA's restrictions against prescription drug advertising: more hindrance than help.
    Lorman AJ.
    Healthspan; 1991 Nov; 8(10):3-7. PubMed ID: 10114942
    [No Abstract] [Full Text] [Related]

  • 22. Orphan drugs and orphan tests in the USA.
    Thoene JG.
    Community Genet; 2004 Nov; 7(4):169-72. PubMed ID: 15692190
    [No Abstract] [Full Text] [Related]

  • 23. 1992 Le Tourneau Award. Problems with pharmaceutical regulation in the United States. Drug lag and orphan drugs.
    Henry V.
    J Leg Med; 1993 Dec; 14(4):617-39. PubMed ID: 8308452
    [No Abstract] [Full Text] [Related]

  • 24. Wyeth preemption case ruling sparks labeling confusion.
    Allison M.
    Nat Biotechnol; 2009 May; 27(5):399-400. PubMed ID: 19430423
    [No Abstract] [Full Text] [Related]

  • 25. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL.
    Food Drug Law J; 2005 May; 60(2):261-338. PubMed ID: 16094773
    [No Abstract] [Full Text] [Related]

  • 26. US Congress to consider limits on DTCA.
    Guthrie P.
    CMAJ; 2007 May 08; 176(10):1404. PubMed ID: 17485685
    [No Abstract] [Full Text] [Related]

  • 27. U.S. v. Barr Laboratories: a technical perspective.
    Madsen RE.
    PDA J Pharm Sci Technol; 1994 May 08; 48(4):176-9. PubMed ID: 7804814
    [No Abstract] [Full Text] [Related]

  • 28. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR.
    Suffolk Univ Law Rev; 2003 May 08; 36(3):787-819. PubMed ID: 16493844
    [No Abstract] [Full Text] [Related]

  • 29. Prescription drug advertising--should states regulate what is false and misleading?
    Shaeffer J.
    Food Drug Law J; 2003 May 08; 58(4):629-48. PubMed ID: 15027454
    [No Abstract] [Full Text] [Related]

  • 30. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H.
    Food Drug Law J; 2003 May 08; 58(1):51-80. PubMed ID: 12739584
    [No Abstract] [Full Text] [Related]

  • 31. US aims to tighten rules on direct-to-consumer drug ads.
    Vastag B.
    Nat Biotechnol; 2007 Mar 08; 25(3):267. PubMed ID: 17344868
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC.
    Food Drug Law J; 2004 Mar 08; 59(1):155-68. PubMed ID: 15190929
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.